# Buccal mucosa and gingivobuccal cancer (oral cancer in India)

Source: https://onco.cc/cancers/buccal-mucosa-cancer/  
OnCo record `buccal-mucosa-cancer` (Cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Cancer of the cheek lining and gums is India's commonest cancer in men, caused by chewing tobacco and areca nut. Surgery with reconstruction is the mainstay, and trials from Tata Memorial in Mumbai have shown that removing the neck nodes up front, cheap oral chemotherapy, tiny doses of immunotherapy and visual screening by health workers all save lives at low cost.

## Summary

Squamous cell carcinoma of the buccal mucosa, gingivobuccal sulcus, lower alveolus and retromolar trigone is the characteristic oral cancer of South Asia, where smokeless tobacco (gutka, khaini, mawa) and areca nut are held against the cheek for hours a day. It is often preceded by leukoplakia or by oral submucous fibrosis, the areca-nut induced stiffening of the cheek that limits mouth opening and hides tumours. The Kerala trial, reported by Sankaranarayanan in 2005, showed that visual oral examination by trained health workers cut oral cancer deaths in tobacco or alcohol users by about a third, the only randomised evidence for oral cancer screening.

Surgery is the mainstay: wide excision with marginal or segmental mandibulectomy for bone involvement, clearance of the infratemporal fossa when the masticator space is involved, neck dissection and free-flap reconstruction with anterolateral thigh or fibula flaps. The Tata Memorial trial of elective neck dissection, reported by D'Cruz in 2015 in 596 patients with early node-negative oral cancer, showed three-year overall survival of 80.0 against 67.5 percent, and Tata Memorial surgeons have redefined which tumours invading the masticator space can still be resected; induction docetaxel-cisplatin-fluorouracil is used to make borderline tumours operable. Postoperative radiotherapy or cisplatin chemoradiation follows for advanced stage, extranodal extension or positive margins.

Because most Indian patients present late and few can afford imported drugs, Tata Memorial trials have built a low-cost palliative pathway: oral methotrexate with celecoxib beat intravenous cisplatin (median survival 7.5 against 6.1 months, with fewer serious side effects); adding nivolumab at one-twentieth of the usual dose raised one-year survival from 16.3 to 43.4 percent; and METRO PLUS in Varanasi doubled median survival from 5 to 10 months by adding metronomic tablets to paclitaxel-carboplatin. Tobacco control, state bans on gutka and screening are the levers for prevention, and incidence is still rising.

## Fields

- Kind: Cancer
- Last checked: 2026-09-17
- Also known as: Gingivobuccal complex cancer; Cheek cancer; Betel quid-associated oral cancer; Indian oral cancer
- Tags: subtype-page; head-and-neck
- Group: head and neck
- Burden: India carries about a third of the world's oral cancers, and the gingivobuccal complex (the cheek lining, the gums and the sulcus between them) is the commonest site there because chewed tobacco and areca nut sit in the cheek pouch; it is the leading cancer in Indian men.
- Subtypes: Buccal mucosa squamous cell carcinoma; Gingivobuccal sulcus and lower alveolus (gum) cancer; Retromolar trigone cancer; Cancer arising in oral submucous fibrosis (areca nut); Verrucous carcinoma of the buccal mucosa
- Biomarkers: Depth of invasion and bone invasion (marginal versus segmental mandibulectomy); Masticator space involvement (resectability); Extranodal extension and margin status; Oral submucous fibrosis and leukoplakia (precursors); TP53 mutation; PD-L1 combined positive score (recurrent disease)

## Sections of this record

The page is a hub with ten sections in reading order; large sections have their own page. The same plan as JSON: https://onco.cc/api/v1/cancers/buccal-mucosa-cancer/sections.json

- Overview (on the hub): The TL;DR, the family this cancer belongs to, the organ, who gets it and what the state of the art is. https://onco.cc/cancers/buccal-mucosa-cancer/#overview [3 state-of-the-art points]
- Types and stages (on the hub): Anatomy, the subtypes and how they differ, how it is staged, and where advanced disease spreads. https://onco.cc/cancers/buccal-mucosa-cancer/#what-it-is [5 subtypes]
- Symptoms and diagnosis (on the hub): How this cancer shows itself, how the diagnosis is confirmed, and the biomarkers clinicians test for. https://onco.cc/cancers/buccal-mucosa-cancer/#finding-it [6 biomarkers]
- Treatment (on the hub): The standard of care by setting, the medicines, surgery and radiotherapy named in it, and the regimens behind them. https://onco.cc/cancers/buccal-mucosa-cancer/#treating-it [6 settings, 4 decisions with options]
- Trials and papers (on the hub): Trials recruiting now, the landmark trials, the trials held by this cancer's subtypes, the key papers and what they mean, the latest literature, and the milestones year by year. https://onco.cc/cancers/buccal-mucosa-cancer/#evidence [6 trials, 4 key papers, 6 milestones]
- Biology and targets (on the hub): The molecular landscape: the targets and how often each appears, the pathways, the mechanics stages and the preclinical models. https://onco.cc/cancers/buccal-mucosa-cancer/#science [2 targets]
- Countries and centres (own page): Cases by country, the UK and NHS pathway and other country lenses, the expert centres with trials on record, and the centres named on this cancer's subtypes. https://onco.cc/cancers/buccal-mucosa-cancer/where-you-are/ [3 centres]
- Decisions and support (on the hub): The decisions you may face, the aids that walk through them, the warnings on record, the first sixty days and the questions to ask. https://onco.cc/cancers/buccal-mucosa-cancer/#living-with-it [21 questions, 6 red cards]
- Pipeline and open problems (own page): Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record. https://onco.cc/cancers/buccal-mucosa-cancer/coming/ [7 medicines, 5 trials, 4 open problems]
- Data (own page): Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked. https://onco.cc/cancers/buccal-mucosa-cancer/data/ [36 connected records]

## Standard of care

- Screening in high-risk populations: Visual oral examination by trained health workers for tobacco and alcohol users (Kerala trial); treatment of leukoplakia and management of oral submucous fibrosis. ([Kerala oral cancer visual screening trial (Trivandrum)](https://onco.cc/trials/kerala-oral-screening/), [Oral cancer visual screening](https://onco.cc/technologies/oral-visual-screening/))
- Resectable disease: Wide excision with marginal or segmental mandibulectomy as needed, elective or therapeutic neck dissection (Tata Memorial trial), and free-flap reconstruction. ([Elective vs therapeutic neck dissection in node-negative oral cancer (Tata Memorial)](https://onco.cc/trials/elective-neck-dissection-tmh/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/))
- Borderline resectable (masticator space involvement): Induction docetaxel-cisplatin-fluorouracil to shrink technically unresectable tumours, then surgery in responders (Tata Memorial practice); chemoradiation otherwise. ([Docetaxel](https://onco.cc/drugs/docetaxel/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Fluorouracil (5-FU)](https://onco.cc/drugs/fluorouracil/), [Chemoradiation (chemoradiotherapy, CRT)](https://onco.cc/terms/chemoradiation/))
- After surgery: Postoperative radiotherapy for advanced stage, perineural invasion or nodes; cisplatin chemoradiation for extranodal extension or positive margins. ([IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Chemoradiation (chemoradiotherapy, CRT)](https://onco.cc/terms/chemoradiation/))
- Palliative and recurrent disease: Oral metronomic methotrexate with celecoxib; low-dose nivolumab added where affordable; metronomic tablets with paclitaxel-carboplatin (METRO PLUS); pembrolizumab where available. ([Methotrexate](https://onco.cc/drugs/methotrexate/), [Oral metronomic chemotherapy vs intravenous cisplatin (Tata Memorial)](https://onco.cc/trials/metronomic-vs-cisplatin-tmh/), [Nivolumab](https://onco.cc/drugs/nivolumab/), [Low-dose nivolumab plus metronomic chemotherapy (Tata Memorial)](https://onco.cc/trials/low-dose-nivolumab-tmh/), [METRO PLUS (Tata Memorial Centre, Varanasi)](https://onco.cc/trials/metro-plus-varanasi/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/))
- Prevention: Smokeless tobacco and areca nut cessation, gutka bans, and oral screening in high-risk people. ([Smoking cessation in cancer patients](https://onco.cc/technologies/smoking-cessation-after-diagnosis/), [Oral cancer visual screening](https://onco.cc/technologies/oral-visual-screening/))

## State of the art

- Tata Memorial trials have produced category 1 evidence for elective neck dissection and the only randomised evidence for oral cancer screening.
- Low-cost metronomic chemotherapy and low-dose immunotherapy are now standards for palliative care across South Asia.
- Compartment surgery and free-flap reconstruction have made resection of masticator-space tumours possible.

## Open problems

- Late presentation and rising incidence as areca nut and gutka use spread.
- Access to pembrolizumab, cetuximab and radiotherapy machines outside big cities.
- Whether low-dose immunotherapy matches full-dose treatment.
- Trismus and eating after cheek and jaw resection.

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Oral_cancer
- Wikipedia: https://en.wikipedia.org/wiki/Oral_cancer

## Connected records

- cancers: [Lip cancer](https://onco.cc/cancers/lip-cancer/), [Oral cavity cancer (mouth and tongue)](https://onco.cc/cancers/oral-cavity-cancer/), [Oral tongue and floor of mouth cancer](https://onco.cc/cancers/oral-tongue-cancer/)
- drugs: [Celecoxib](https://onco.cc/drugs/celecoxib/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Docetaxel](https://onco.cc/drugs/docetaxel/), [Fluorouracil (5-FU)](https://onco.cc/drugs/fluorouracil/), [Methotrexate](https://onco.cc/drugs/methotrexate/), [Nivolumab](https://onco.cc/drugs/nivolumab/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- institutions: [Advanced Centre for Treatment, Research and Education in Cancer](https://onco.cc/institutions/actrec/), [Homi Bhabha Cancer Hospital and Mahamana Pandit Madan Mohan Malaviya Cancer Centre, Varanasi](https://onco.cc/institutions/homi-bhabha-cancer-hospital-varanasi/), [Tata Memorial Centre](https://onco.cc/institutions/tata-memorial/)
- terms: [Chemoradiation (chemoradiotherapy, CRT)](https://onco.cc/terms/chemoradiation/), [Depth of invasion (DOI)](https://onco.cc/terms/depth-of-invasion/), [Extranodal extension (ENE)](https://onco.cc/terms/extranodal-extension/)
- key papers: [Effect of screening on oral cancer mortality in Kerala, India](https://onco.cc/key-papers/paper-sankaranarayanan-oral-screening-lancet-2005/), [Elective versus therapeutic neck dissection in node-negative oral cancer](https://onco.cc/key-papers/paper-dcruz-elective-neck-dissection-nejm-2015/), [EORTC 22931: postoperative irradiation with or without concomitant cisplatin for locally advanced head and neck cancer](https://onco.cc/key-papers/paper-bernier-eortc-22931-nejm-2004/), [RTOG 9501: postoperative concurrent radiotherapy and chemotherapy for high-risk head and neck squamous cell carcinoma](https://onco.cc/key-papers/paper-cooper-rtog-9501-nejm-2004/)
- trials: [Elective vs therapeutic neck dissection in node-negative oral cancer (Tata Memorial)](https://onco.cc/trials/elective-neck-dissection-tmh/), [Kerala oral cancer visual screening trial (Trivandrum)](https://onco.cc/trials/kerala-oral-screening/), [Low-dose nivolumab plus metronomic chemotherapy (Tata Memorial)](https://onco.cc/trials/low-dose-nivolumab-tmh/), [METRO PLUS (Tata Memorial Centre, Varanasi)](https://onco.cc/trials/metro-plus-varanasi/), [NIVOPOSTOP (GORTEC 2018-01)](https://onco.cc/trials/nivopostop/), [Oral metronomic chemotherapy vs intravenous cisplatin (Tata Memorial)](https://onco.cc/trials/metronomic-vs-cisplatin-tmh/)
- technologies: [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/), [Oral cancer visual screening](https://onco.cc/technologies/oral-visual-screening/), [Smoking cessation in cancer patients](https://onco.cc/technologies/smoking-cessation-after-diagnosis/)

---
JSON: https://onco.cc/api/v1/entities/buccal-mucosa-cancer.json